135 related articles for article (PubMed ID: 12706862)
1. Lack of Fas (APO-1/CD95) gene structural alterations or transcript variant ratio changes in breast cancer.
Puiu L; Petrakou E; Apostolidou A; Athanassiadou A; Psiouri L; Papachatzopoulou A; Gorgoulis VG; Kotsinas A; Tzoracoeleftherakis E; Maniatis GM; Voutsinas G
Cancer Lett; 2003 May; 194(1):91-7. PubMed ID: 12706862
[TBL] [Abstract][Full Text] [Related]
2. Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer.
Boldrini L; Faviana P; Pistolesi F; Gisfredi S; Di Quirico D; Lucchi M; Mussi A; Angeletti CA; Baldinotti F; Fogli A; Simi P; Basolo F; Fontanini G
Oncogene; 2001 Oct; 20(45):6632-7. PubMed ID: 11641789
[TBL] [Abstract][Full Text] [Related]
3. Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO-1) in adult T-cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis.
Kamihira S; Yamada Y; Tomonaga M; Sugahara K; Tsuruda K
Br J Haematol; 1999 Dec; 107(4):851-60. PubMed ID: 10606894
[TBL] [Abstract][Full Text] [Related]
4. CD95 (APO-1/FAS) deficiency in infant acute lymphoblastic leukemia: detection of novel soluble Fas splice variants.
Wood CM; Goodman PA; Vassilev AO; Uckun FM
Eur J Haematol; 2003 Mar; 70(3):156-71. PubMed ID: 12605660
[TBL] [Abstract][Full Text] [Related]
5. Mutations of Fas (APO-1/CD95) and p53 genes in nonmelanoma skin cancer.
Boldrini L; Loggini B; Gisfredi S; Zucconi Y; Baldinotti F; Fogli A; Simi P; Cervadoro G; Barachini P; Basolo F; Pingitore R; Fontanini G
J Cutan Med Surg; 2003; 7(2):112-8. PubMed ID: 12447615
[TBL] [Abstract][Full Text] [Related]
6. Resistance to Fas-Mediated Apoptosis Does Not Correlate to Structural Alterations or Expression Changes of the Death Receptor in Papillary Thyroid Carcinomas.
; Saetta AA; Lazaris AC; Miaouli M; Voutsinas GE; Patsouris E; Tseleni-Balafouta S
Pathobiology; 2018; 85(5-6):304-310. PubMed ID: 30278467
[TBL] [Abstract][Full Text] [Related]
7. Soluble Fas/Apo-1 splicing variants and apoptosis.
Cascino I; Papoff G; Eramo A; Ruberti G
Front Biosci; 1996 Jan; 1():d12-8. PubMed ID: 9159204
[TBL] [Abstract][Full Text] [Related]
8. Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer.
Boldrini L; Faviana P; Gisfredi S; Di Quirico D; Lucchi M; Mussi A; Angeletti CA; Baldinotti F; Fogli A; Simi P; Basolo F; Pingitore F; Fontanini G
Int J Oncol; 2002 Jan; 20(1):155-9. PubMed ID: 11743657
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations in the death domain of the Fas (Apo-1/CD95) gene in gastric cancer.
Park WS; Oh RR; Kim YS; Park JY; Lee SH; Shin MS; Kim SY; Kim PJ; Lee HK; Yoo NY; Lee JY
J Pathol; 2001 Feb; 193(2):162-8. PubMed ID: 11180161
[TBL] [Abstract][Full Text] [Related]
10. Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene.
Müschen M; Re D; Betz B; Moers C; Wolf J; Niederacher D; Diehl V; Beckmann MW
Int J Cancer; 2001 Apr; 92(2):309-10. PubMed ID: 11291062
[TBL] [Abstract][Full Text] [Related]
11. Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines.
Fellenberg J; Mau H; Scheuerpflug C; Ewerbeck V; Debatin KM
Int J Cancer; 1997 Jul; 72(3):536-42. PubMed ID: 9247301
[TBL] [Abstract][Full Text] [Related]
12. Fas gene mutation in the progression of adult T cell leukemia.
Maeda T; Yamada Y; Moriuchi R; Sugahara K; Tsuruda K; Joh T; Atogami S; Tsukasaki K; Tomonaga M; Kamihira S
J Exp Med; 1999 Apr; 189(7):1063-71. PubMed ID: 10190897
[TBL] [Abstract][Full Text] [Related]
13. Soluble Fas (APO-1/CD95) isoform in adult T-cell leukemia.
Kamihira S; Yamada Y
Leuk Lymphoma; 2001 Mar; 41(1-2):169-76. PubMed ID: 11342370
[TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis.
Li JH; Kluger MS; Madge LA; Zheng L; Bothwell AL; Pober JS
Am J Pathol; 2002 Oct; 161(4):1485-95. PubMed ID: 12368221
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide-mediated apoptosis in human breast cancer cells requires changes in mitochondrial functions and is independent of CD95 (APO-1/Fas).
Umansky V; Ushmorov A; Ratter F; Chlichlia K; Bucur M; Lichtenauer A; Rocha M
Int J Oncol; 2000 Jan; 16(1):109-17. PubMed ID: 10601555
[TBL] [Abstract][Full Text] [Related]
16. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia.
Beltinger C; Kurz E; Böhler T; Schrappe M; Ludwig WD; Debatin KM
Blood; 1998 May; 91(10):3943-51. PubMed ID: 9573033
[TBL] [Abstract][Full Text] [Related]
17. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer.
Lee SH; Shin MS; Park WS; Kim SY; Kim HS; Han JY; Park GS; Dong SM; Pi JH; Kim CS; Kim SH; Lee JY; Yoo NJ
Oncogene; 1999 Jun; 18(25):3754-60. PubMed ID: 10391683
[TBL] [Abstract][Full Text] [Related]
18. CD95 ligand expression as a mechanism of immune escape in breast cancer.
Müschen M; Moers C; Warskulat U; Even J; Niederacher D; Beckmann MW
Immunology; 2000 Jan; 99(1):69-77. PubMed ID: 10651943
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene.
Huang QR; Morris D; Manolios N
Mol Immunol; 1997 Jun; 34(8-9):577-82. PubMed ID: 9393960
[TBL] [Abstract][Full Text] [Related]
20. Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells.
Lahiry L; Saha B; Chakraborty J; Adhikary A; Mohanty S; Hossain DM; Banerjee S; Das K; Sa G; Das T
Carcinogenesis; 2010 Feb; 31(2):259-68. PubMed ID: 19969555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
